Evidence map›Paper›PMID 40629911›Full record

ArticleClinical and translational medicine2025

IGF2BP2 binding to CPSF6 facilitates m6A-mediated alternative polyadenylation of PUM2 and promotes malignant progression in ovarian cancer.

Xin Luo, Qinglv Wei, Lingcui Xie, Ningxuan Chen, Bin Gu, Jiani Xu, Xiaoyan Jiang, Xinzhao Zuo, Hongyan Zhao, Xiaoyi Liu and 5 more

Abstract read
In one paragraph

Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xin LuoDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.ORCID 0000-0002-6998-6141
Qinglv WeiChongqing Key Laboratory of Child Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.
Lingcui XieDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Ningxuan ChenDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Bin GuSchool of Basic Medicine, Chongqing Medical University, Chongqing, P.R. China.
Jiani XuDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Xiaoyan JiangDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Xinzhao ZuoDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Hongyan ZhaoSchool of Basic Medicine, Hubei University of Medicine, Shiyan, P.R. China.
Xiaoyi LiuDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Yu YangDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Tao LiuDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.
Yong ZhuSchool of Basic Medicine, Chongqing Medical University, Chongqing, P.R. China.
Ping YiDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.ORCID 0000-0001-7111-6308
Jing XuDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, P.R. China.

Funding

Chongqing Graduate Research Innovation Project CYB21197CQMU Program for Youth Innovation in Future Medicine W0058National Natural Science Foundation of China 82172778Program for Key Disciplines Construction from Third Affiliated Hospital of Chongqing Medical University ZK202004Third Affiliated Hospital of Chongqing Medical University KY23039
6 · The paper itself

Abstract

backgroundN6-methyladenosine (m6A) and alternative polyadenylation (APA) are common posttranscriptional regulatory mechanisms in eukaryotes. However, the m6A-dependent mechanism of APA regulation in ovarian cancer (OC) is still unclear.

methodsThe correlation between m6A and APA was analyzed by using RNA methylation sequencing of OC cells and single-cell sequencing of clinical samples from public databases. To explore the core regulatory factors that served as a bridge between m6A and APA, we employed RNA pull-down with biotin-labelled m6A, immunoprecipitation, mass spectrometry, western blot, protein purification and GST pull-down assays. Furthermore, the important target genes were screened by PAS-seq, eCLIP-seq, RIP-seq and meRIP-seq, and verified by RT-qPCR, 3'RACE, RNA stability, and dual luciferase reporter assays. Multiple phenotypic experiments were conducted to evaluate the function of the IGF2BP2-PUM2 axis in vitro and in vivo.

resultsThis study found that the m6A was correlated with the APA and affected the 3'end processing in OC. The APA regulator CPSF6 tended to bind the m6A-modified transcripts in OC cells. Mechanistically, we demonstrated that the m6A reader IGF2BP2 KH1-4 domains could directly bind to the CPSF6-RS domain to regulate the 3'end processing of OC. Furthermore, sequencing revealed that the m6A was highly enriched in the 3'UTR near the proximal polyadenylation signal (PAS), which promotes the use of proximal PAS and leads to 3'UTR shortening. PUM2 was carried m6A and recognized by IGF2BP2, and CPSF6 was recruited at the proximal polyadenylation signal (pPAS) to generate the short-3'UTR transcript. The short PUM2 transcript was more stable than the long transcript, which promoted the malignant progression of OC.

conclusionsWe revealed a novel mechanism in which the m6A could regulate the APA processing of pre-mRNAs by crosstalk of IGF2BP2 and CPSF6. This study provides a potential strategy for the effective treatment of OC. HIGHLIGHTS: The interaction between m6A and APA is mediated by the m6A regulator IGF2BP2 and the APA factor CPSF6. The transcripts harboring m6A modification tend to use the proximal polyadenylation signal (PAS) in ovarian cancer (OC). PUM2 promotes the malignant progression of OC through its m6A methylation and APA processing.

Indexed as

AdenosineCleavage And Polyadenylation Specificity FactormRNA Cleavage and Polyadenylation FactorsOvarian NeoplasmsPolyadenylationRNA-Binding ProteinsAnimalsCell Line, TumorDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMiceAdenosineCleavage And Polyadenylation Specificity FactorIGF2BP2 protein, humanmRNA Cleavage and Polyadenylation FactorsN-methyladenosinePUM2 protein, humanRNA-Binding Proteinsalternative polyadenylationCPSF6IGF2BP2N6‐methyladenosineovarian cancerPUM2

Identifiers

PMID40629911
PMCPMC12238680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.